+357 96 030922
info@marketpublishers.com

Oral Proteins and Peptides Market Size, Share and Growth Outlook 2026: By Drug Class (GLP-1 Peptides, Somatostatin Analogs, PTH Analogs, GLP-2 Peptides, Insulin, Others), By Therapeutic Area, By Age Group, By Distribution Channel, Companies to 2034.

https://marketpublishers.com/r/OFCC5052A35AEN.html
Date: July 2026
Pages: 190
Price: US$ 3,482.00 (Single User License)
ID: OFCC5052A35AEN

Abstracts

The global Oral Proteins and Peptides Market size is forecast to increase from $10.23 Billion in 2026 to $32.69 Billion in 2034 at a CAGR of 15.63% between 2026 and 2034.

The Oral Proteins and Peptides market report provides detailed analysis and outlook of Oral Proteins and Peptides segments including By Drug Class (GLP-1 Peptides, Somatostatin Analogs, PTH Analogs, GLP-2 Peptides, Insulin, Others), By Therapeutic Area (Metabolic Disorders, Endocrine Disorders, Gastric and Digestive Disorders, Bone Diseases, Hormonal Disorders), By Age Group (Adult, Pediatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Specialty Pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Oral Proteins and Peptides Industry Overview

Advances in Drug Delivery Technologies Accelerate the Commercialization of Oral Protein and Peptide Therapeutics

The oral proteins and peptides industry is undergoing rapid advancement as pharmaceutical companies pursue alternatives to injectable biologics through innovative drug delivery technologies and formulation platforms. Historically limited by poor gastrointestinal stability, enzymatic degradation, and low bioavailability, oral delivery of

proteins and peptides is now becoming increasingly feasible due to breakthroughs in absorption enhancement technologies, protective formulations, encapsulation systems, and controlled-release mechanisms. Growing demand for patient-friendly therapeutics, improved treatment adherence, and expanded access to biologic medicines is driving substantial investment across oral peptide therapeutics, nutraceutical peptides, and functional protein ingredients. Pharmaceutical developers, contract research organizations, and ingredient manufacturers are collaborating to overcome traditional barriers to oral administration while expanding therapeutic opportunities across metabolic disorders, osteoporosis, neurology, gastrointestinal diseases, and cognitive health applications.

Clinical Validation and Novel Functional Peptides Expand Commercial Opportunities

The increasing availability of clinical evidence supporting orally administered peptides is strengthening industry confidence and accelerating commercialization efforts. The launch of PeptiDrive-LNDP by Maypro illustrates the growing market for clinically validated oral peptide ingredients targeting cognitive wellness applications. Derived from casein through enzymatic hydrolysis, this 19-amino-acid peptide has demonstrated favorable pharmacokinetic characteristics, oral stability, and clinical efficacy supporting memory and attention functions. Simultaneously, pharmaceutical developers are advancing therapeutic-grade oral peptide candidates with the objective of replacing injectable treatments. At the Endocrine Society's ENDO conference, Entera Bio presented Phase 1 clinical data demonstrating that its oral PTH(1-34) candidate, EB613, achieved pharmacokinetic and pharmacodynamic profiles comparable to injectable bone-building therapies, reinforcing the potential for oral peptide formulations to transform osteoporosis treatment paradigms.

Advanced Delivery Platforms Address Bioavailability and Gastrointestinal Stability Challenges

Technological innovation in oral drug delivery systems remains a primary growth driver across the proteins and peptides ecosystem. Pharmaceutical developers are increasingly adopting multifunctional delivery platforms designed to protect biologically active molecules from gastrointestinal degradation while enhancing intestinal absorption and systemic bioavailability. Reflecting this trend, Protheragen introduced an integrated development platform focused on advanced oral delivery technologies for proteins, peptides, and nucleic acids, including hydrogel-based delivery systems and lyophilized flash-release formulations engineered to preserve therapeutic integrity during gastrointestinal transit. These advancements are supporting broader industry transitions toward non-invasive biologic therapies, enabling pharmaceutical companies to expand pipeline opportunities while addressing patient preference for oral treatment options across chronic and specialty disease indications.

Oral Proteins and Peptides Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Oral Proteins and Peptides market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Novo Nordisk A/S, AbbVie Inc., Pfizer Inc., Eli Lilly and Company, Oramed Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Biocon Limited, AstraZeneca PLC, Sanofi S.A., Novartis AG. The Oral Proteins and Peptides market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Oral Proteins and Peptides industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

- Growth Oral Proteins and Peptides Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Oral Proteins and Peptides companies

- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

- Detailed SWOT Analysis of global and regional Oral Proteins and Peptides markets

- Competitive analysis including business description, product analysis, and financial profiles

- Key country specific analysis detailing key factors shaping the short-term and long-term outlook

Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Oral Proteins and Peptides Market Competitive Benchmarking and Company Analysis

Leading companies in Oral Proteins and Peptides industry include- Novo Nordisk A/S, AbbVie Inc., Pfizer Inc., Eli Lilly and Company, Oramed Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Biocon Limited, AstraZeneca PLC, Sanofi S.A., Novartis AG. The Oral Proteins and Peptides market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Oral Proteins and Peptides Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Oral Proteins and Peptides market remains one of the strongest-performing segments in the country.

The US Oral Proteins and Peptides Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Oral Proteins and Peptides market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Oral Proteins and Peptides industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Oral Proteins and Peptides markets

Canada's strong Oral Proteins and Peptides sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Oral Proteins and Peptides market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Oral Proteins and Peptides Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Oral Proteins and Peptides market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Oral Proteins and Peptides population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Oral Proteins and Peptides industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Oral Proteins and Peptides market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Oral Proteins and Peptides sales through 2034

France Oral Proteins and Peptides companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control

+357 96 030922
info@marketpublishers.com

measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Oral Proteins and Peptides Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Oral Proteins and Peptides distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Oral Proteins and Peptides Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Oral Proteins and Peptides market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Oral Proteins and Peptides industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was

95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Oral Proteins and Peptides industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Oral Proteins and Peptides Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Oral Proteins and Peptides market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Oral Proteins and Peptides market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Oral Proteins and Peptides Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Oral Proteins and Peptides Market Segmentation

By Drug Class

GLP-1 Peptides

Somatostatin Analogs

PTH Analogs

GLP-2 Peptides

Insulin

Others

By Therapeutic Area

Metabolic Disorders

Endocrine Disorders

Gastric and Digestive Disorders

Bone Diseases

Hormonal Disorders

By Age Group

Adult

Pediatric

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies and Drug Stores

Specialty Pharmacies

Leading Companies in Oral Proteins and Peptides Industry (2026)

Novo Nordisk A/S

AbbVie Inc.

Pfizer Inc.

Eli Lilly and Company

Oramed Pharmaceuticals Inc.

Chiesi Farmaceutici S.p.A.

Biocon Limited

AstraZeneca PLC

Sanofi S.A.

Novartis AG

Countries Included

- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others

+357 96 030922
info@marketpublishers.com

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market developments

Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry

Contents

+357 96 030922
info@marketpublishers.com

CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK

CHAPTER 7- NORTH AMERICA ORAL PROTEINS AND PEPTIDES MARKET SIZE ANALYSIS AND OUTLOOK

+357 96 030922
info@marketpublishers.com

CHAPTER 9- ASIA PACIFIC ORAL PROTEINS AND PEPTIDES MARKET SIZE ANALYSIS AND OUTLOOK

CHAPTER 10- SOUTH AND CENTRAL AMERICA ORAL PROTEINS AND PEPTIDES MARKET SIZE ANALYSIS AND OUTLOOK

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Oral Proteins and Peptides Market Size, Share and Growth Outlook 2026: By Drug Class (GLP-1 Peptides, Somatostatin Analogs, PTH Analogs, GLP-2 Peptides, Insulin, Others), By Therapeutic Area, By Age Group, By Distribution Channel, Companies to 2034.

Product link: https://marketpublishers.com/r/OFCC5052A35AEN.html

Price: US$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/OFCC5052A35AEN.html